Jasper Therapeutics, Inc. (NASDAQ:JSPR) Receives $62.22 Consensus Price Target from Analysts

Jasper Therapeutics, Inc. (NASDAQ:JSPRGet Free Report) has been given a consensus rating of “Buy” by the nine analysts that are currently covering the firm, MarketBeat reports. Nine equities research analysts have rated the stock with a buy recommendation. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $59.25.

A number of research analysts have recently issued reports on the company. Oppenheimer dropped their price objective on Jasper Therapeutics from $80.00 to $65.00 and set an “outperform” rating on the stock in a research note on Thursday, May 15th. HC Wainwright reissued a “buy” rating and issued a $40.00 price objective on shares of Jasper Therapeutics in a research note on Tuesday, March 11th. Finally, UBS Group dropped their price objective on Jasper Therapeutics from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, May 13th.

Get Our Latest Report on Jasper Therapeutics

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN boosted its holdings in Jasper Therapeutics by 106.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,415 shares of the company’s stock worth $159,000 after acquiring an additional 3,828 shares in the last quarter. EntryPoint Capital LLC bought a new position in shares of Jasper Therapeutics in the fourth quarter valued at approximately $223,000. Acadian Asset Management LLC bought a new position in shares of Jasper Therapeutics in the first quarter valued at approximately $46,000. Tema Etfs LLC bought a new position in shares of Jasper Therapeutics in the fourth quarter valued at approximately $266,000. Finally, Rhumbline Advisers lifted its holdings in shares of Jasper Therapeutics by 12.6% in the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company’s stock valued at $316,000 after purchasing an additional 1,652 shares in the last quarter. Institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Stock Performance

Jasper Therapeutics stock opened at $5.49 on Wednesday. The firm has a 50 day moving average price of $5.17 and a two-hundred day moving average price of $7.48. Jasper Therapeutics has a 52-week low of $3.13 and a 52-week high of $26.05. The firm has a market cap of $82.46 million, a price-to-earnings ratio of -1.05 and a beta of 2.72.

Jasper Therapeutics (NASDAQ:JSPRGet Free Report) last released its earnings results on Monday, May 12th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.24). As a group, equities research analysts predict that Jasper Therapeutics will post -4.47 EPS for the current fiscal year.

About Jasper Therapeutics

(Get Free Report

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.

See Also

Analyst Recommendations for Jasper Therapeutics (NASDAQ:JSPR)

Receive News & Ratings for Jasper Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jasper Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.